2023
Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials
Rediti M, Fernandez-Martinez A, Venet D, Rothé F, Hoadley K, Parker J, Singh B, Campbell J, Ballman K, Hillman D, Winer E, El-Abed S, Piccart M, Di Cosimo S, Symmans W, Krop I, Salgado R, Loi S, Pusztai L, Perou C, Carey L, Sotiriou C. Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials. Nature Communications 2023, 14: 7053. PMID: 37923752, PMCID: PMC10624889, DOI: 10.1038/s41467-023-42635-2.Peer-Reviewed Original ResearchConceptsEvent-free survivalHER2-positive breast cancerPathological complete responseCALGB 40601Breast cancerBreast pathological complete responseStromal tumor-infiltrating lymphocytesHormone receptor statusPhase III trialsClinical nodal statusIndependent prognostic factorTumor-infiltrating lymphocytesIdentification of patientsBreast cancer prognosisT cell receptorNeoadjuvant paclitaxelNeoadjuvant therapyIII trialsNodal statusComplete responsePrognostic factorsPrognostic scoreReceptor statusClinicopathological featuresResidual diseaseNodal positivity and systemic therapy among patients with clinical T1–T2N0 human epidermal growth factor receptor‐positive breast cancer: Results from two international cohorts
Weiss A, Martínez‐Sáez O, Waks A, Laws A, McGrath M, Tarantino P, Portnow L, Winer E, Rey M, Tapia M, Prat A, Partridge A, Tolaney S, Cejalvo J, Mittendorf E, King T. Nodal positivity and systemic therapy among patients with clinical T1–T2N0 human epidermal growth factor receptor‐positive breast cancer: Results from two international cohorts. Cancer 2023, 129: 1836-1845. PMID: 36951169, DOI: 10.1002/cncr.34750.Peer-Reviewed Original ResearchConceptsHER2-positive breast cancerNeoadjuvant chemotherapyUpfront surgeryNodal positivityBreast cancerTumor sizeALND ratesCT1c tumorsTreatment strategiesSmall human epidermal growth factor receptor 2Lymph node dissection ratesReceptor-positive breast cancerHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Clinical T1-T2Lymph node positiveHER2-positive patientsGrowth factor receptor 2Optimal treatment strategyFactor receptor 2Nodal statusSystemic therapyNode positiveAxillary imagingPositive tumors
2021
Twenty-year risks of breast cancer-specific mortality for stage III breast cancer in the surveillance, epidemiology, and end results registry
Leone JP, Leone BA, Tayob N, Hassett MJ, Leone J, Freedman RA, Tolaney SM, Winer EP, Vallejo CT, Lin NU. Twenty-year risks of breast cancer-specific mortality for stage III breast cancer in the surveillance, epidemiology, and end results registry. Breast Cancer Research And Treatment 2021, 187: 843-852. PMID: 33590387, DOI: 10.1007/s10549-021-06121-x.Peer-Reviewed Original ResearchConceptsRisk of BCSMBreast cancer-specific mortalityStage III breast cancerHR-negative diseaseHR-positive diseaseCancer-specific mortalityBreast cancerLate deathsNodal statusTumor sizeUnknown hormone receptor statusHR-positive tumorsEnd Results registryHormone receptor statusEnd Results (SEER) dataTraditional clinicopathologic factorsCumulative incidence functionGray regressionMethodsUsing SurveillanceAxillary nodesClinicopathologic factorsReceptor statusStage subgroupsPrimary tumorTumor grade
2020
Primary analysis of KAITLIN: A phase III study of trastuzumab emtansine (T-DM1) + pertuzumab versus trastuzumab + pertuzumab + taxane, after anthracyclines as adjuvant therapy for high-risk HER2-positive early breast cancer (EBC).
Harbeck N, Im S, Barrios C, Bonnefoi H, Gralow J, Toi M, Ellis P, Gianni L, Swain S, Im Y, De Laurentiis M, Nowecki Z, Shah J, Boulet T, Liu H, Macharia H, Trask P, Song C, Winer E, Krop I. Primary analysis of KAITLIN: A phase III study of trastuzumab emtansine (T-DM1) + pertuzumab versus trastuzumab + pertuzumab + taxane, after anthracyclines as adjuvant therapy for high-risk HER2-positive early breast cancer (EBC). Journal Of Clinical Oncology 2020, 38: 500-500. DOI: 10.1200/jco.2020.38.15_suppl.500.Peer-Reviewed Original ResearchHER2-positive early breast cancerInvasive disease-free survivalEarly breast cancerPatient-reported outcomesCo-primary endpointsStandard of careT-DM1ITT populationOverall survivalAnthracycline-based chemotherapyOpen-label studyDisease-free survivalPhase III studyWeeks of surgeryHigh-risk populationChemotherapy-associated toxicityAdjuvant taxanesConcurrent trastuzumabEndocrine therapySecondary endpointsAdjuvant radiotherapyAdjuvant therapyIII studyNodal statusMore patients
2017
Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative)
Ollila DW, Cirrincione CT, Berry DA, Carey LA, Sikov WM, Hudis CA, Winer EP, Golshan M. Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative). Journal Of The American College Of Surgeons 2017, 224: 688-694. PMID: 28089784, PMCID: PMC5616181, DOI: 10.1016/j.jamcollsurg.2016.12.036.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAxillaBiopsyBreast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, LobularFemaleHumansLymph Node ExcisionLymph NodesLymphatic MetastasisMastectomyMiddle AgedNeoadjuvant TherapyNeoplasm StagingPractice Patterns, Physicians'Receptor, ErbB-2Sentinel Lymph Node BiopsyTriple Negative Breast NeoplasmsUnited StatesConceptsAxillary lymph node dissectionNeoadjuvant systemic therapyNode-positive patientsSentinel node biopsyStage II/III breast cancerResidual axillary diseaseNode biopsyAxillary diseaseSystemic therapyBreast cancerAxillary node evaluationAxillary surgical proceduresPathologic nodal statusLymph node dissectionNode-positive diseaseCore needle biopsyFine-needle aspirationAxillary evaluationAxillary managementCALGB 40601N0 diseaseAxillary procedureNode dissectionRadiologic stagingNodal status
2012
Preoperative systemic therapy in locoregional management of early breast cancer: highlights from the Kyoto Breast Cancer Consensus Conference
Toi M, Benson JR, Winer EP, Forbes JF, von Minckwitz G, Golshan M, Robertson JF, Sasano H, Cole BF, Chow LW, Pegram MD, Han W, Huang CS, Ikeda T, Kanao S, Lee ES, Noguchi S, Ohno S, Partridge AH, Rouzier R, Tozaki M, Sugie T, Yamauchi A, Inamoto T. Preoperative systemic therapy in locoregional management of early breast cancer: highlights from the Kyoto Breast Cancer Consensus Conference. Breast Cancer Research And Treatment 2012, 136: 919-926. PMID: 23143284, DOI: 10.1007/s10549-012-2333-9.Peer-Reviewed Original ResearchConceptsPreoperative systemic therapyCore needle biopsyMulti-gene signatureSystemic therapyConsensus conferenceHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Fine needle aspiration cytologyEarly breast cancerGrowth factor receptor 2Node-positive casesLikelihood of patientsIndividualized treatment regimensKi67 labeling indexNeedle aspiration cytologyFactor receptor 2Treatment-induced changesCell proliferative activityLymph node diagnosisAxillary surgeryLocoregional managementNodal statusLocal therapySurgical treatmentTreatment algorithm
2007
Heterogeneity of breast cancer and implications of adjuvant chemotherapy
Razzak AR, Lin NU, Winer EP. Heterogeneity of breast cancer and implications of adjuvant chemotherapy. Breast Cancer 2007, 15: 31-34. PMID: 18224391, DOI: 10.1007/s12282-007-0007-y.Peer-Reviewed Original ResearchConceptsEstrogen receptor-positive tumorsReceptor-positive tumorsBreast cancerPositive diseasePositive tumorsAdjuvant chemotherapyDisease recurrenceClinical dataEstrogen receptor-positive cancersEstrogen receptor-negative cancersEstrogen-positive tumorsRole of chemotherapyUse of trastuzumabReceptor-positive cancersTriple-negative tumorsReceptor-negative cancersHigh nuclear gradeBreast cancer treatmentFamily of diseasesEndocrine therapyNodal statusNegative tumorsPositive cancersTumor sizeNegative cancers
1997
Weight Gain in Women Diagnosed with Breast Cancer
WAHNEFRIED W, RIMER B, WINER E. Weight Gain in Women Diagnosed with Breast Cancer. Journal Of The Academy Of Nutrition And Dietetics 1997, 97: 519-529. PMID: 9145091, DOI: 10.1016/s0002-8223(97)00133-8.Peer-Reviewed Original ResearchConceptsBreast cancerWeight gainRisk of recurrenceQuality of lifeIntensity of treatmentQuantity of lifeMultiagent regimensPremenopausal womenMenopausal statusNodal statusWeight managementDietary intakePhysical activityHigh doseRate of metabolismCancerPatientsEffective interventionsDietetics practitionersLonger durationWomenDecrease survivalFurther studiesPsychosocial researchRecent findings